Cellular therapy reverses myocardial dysfunction  by Rajnoch, C. et al.
plications of immunosuppression, and graft failure. As
an alternative, dynamic cardiomyoplasty was developed
in our laboratory1 and clinically applied in 1985.2 The
principle of dynamic cardiomyoplasty is the use of an
electrically stimulated skeletal muscle that is partially
wrapped around the heart to restore or augment ventric-
ular contraction. This surgical procedure provided evi-
dence that an autologous skeletal muscle graft could be
adapted to perform cardiac work and enhance cardiac
function.3 Marelli and associates4 and Chiu5 extended
this method by developing a less-invasive technique,
called cellular cardiomyoplasty, in which satellite cells
or undifferentiated myoblasts were cultured from a
skeletal muscle fragment and implanted into the
myocardium.
Over the past 7 years, primary myoblasts have been
grafted into cryoinjured myocardium of rats,6-8 rab-
bits,9-12 and dogs.4,13,14 In this study, autologous satel-
lite cells were implanted in a novel model of myocar-
dial injury caused by snake cardiotoxin injection.15 The
aims of this study were to show survival and differenti-
I n the United States, an estimated 12 million personshave coronary heart disease, of whom 7 million are
affected by myocardial infarction and 4.6 million by
congestive heart failure (American Heart Association
1999 Heart and Stroke statistical update). As in many
other developed countries, cardiovascular disease is a
leading health problem and a predominant cause of
death. Consequently, there is a desperate need for
awareness, prevention, medication, and surgical treat-
ments.
Cardiac transplantation, which is an efficient solution
to this problem, is limited by a shortage of donors, com-
Objectives: Cellular cardiomyoplasty refers to the implantation of autolo-
gous skeletal muscle cells into the myocardium to reinforce its structure and
function. In this study a reproducible method for the creation of a myocar-
dial lesion was developed. The functional benefit of cell implantation was
evaluated by 2-dimensional echocardiography for global contraction and
color kinesis echocardiography, which allows the precise assessment of the
regional contraction.
Methods: A left ventricular intramyocardial injection with snake cardiotoxin
was carried out on a sheep model to induce a well-delineated transmural
lesion. Three weeks later, the lesion was assessed by echocardiography.
Thereafter, autologous skeletal muscle cells or culture media (control) were
injected into the lesion. Two months after cell implantation, the myocardial
contraction was again evaluated by echocardiography and the implanted
cells were analyzed by a fast myosin heavy chain antibody.
Results: 1. The snake cardiotoxin produced a well-delineated transmural
lesion in all animals. 2. Echocardiographic studies showed a significant
improvement in global and regional left ventricular function in cell-treated
sheep. 3. Histologic analyses demonstrated satellite cell survival at the
periphery of the lesions.
Conclusion: Satellite cells implanted in a cardiotoxin-induced myocardial
lesion survived for a 2-month period and were associated with a significant
functional improvement of both local and global contraction. (J Thorac
Cardiovasc Surg 2001;121:871-8)
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ation of satellite cells in the injured areas of the sheep
myocardium, to assess changes in global function by 2-
dimensional echocardiography, and to assess regional
function by color kinesis echocardiography.
Materials and methods
The animal model. Fifteen sheep weighing 31 ± 6 kg were
divided into 4 groups. In group 1 (n = 3) a myocardial lesion
was effected. In group 2 (n = 3), which served as a control for
group 1, 0.9% sodium chloride was injected into healthy
myocardium. In group 3 (n = 6), myocardial injury was
induced and satellite cell implantation was carried out 3
weeks later. In group 4 (n = 3), which served as a control for
group 3, cells were replaced by culture medium. All animals
were treated according to the guidelines of the French
National Institute of Health and Medical Research
(INSERM).
Anesthetic and postoperative management. All sheep
were deprived of drink and food for 24 hours before the
operation. A premedication of 150 mg acepromazine
(Vetranquil; Sanofi-Synthelabo, Paris, France) was injected
intramuscularly 30 minutes before propofol (Diprivan;
Astra-Zeneca, London, United Kingdom) was injected
intravenously into the left jugular vein at a concentration of
6 mg/kg body weight. The intubation was performed with
an endotracheal probe number 7. Ventilation was assured
with a Siemens 900C respirator (Siemens, Munich,
Germany) using the following parameters: a volume of 10
mL/kg body weight, a frequency of 24 breaths/min, and an
inspired oxygen fraction of 60%. The anesthetic was main-
tained by inhalation of isoflurane (Forene; Abbott
Laboratories, North Chicago, Ill) at 1% to 2%. A gelatin
solution (Plasmion; Fresenius France Pharma, Sevres,
France) was installed as a standard procedure.
Postoperative management of the sheep consisted of ce-
fazolin (Panpharma NV, Gent, Belgium) antibiotics injected
intramuscularly at 1 g a day over a 1-week period.
Skeletal muscle explantation and myocardial injury. A
1 cm3 skeletal muscle fragment was explanted from the left
posterior femoral biceps of each sheep under sterile condi-
tions. The biopsy tissue was kept in Hanks balanced salt
solution (Gibco BRL, Life Technologies, Inc, Rockville,
Md) at 4°C until cell culture was started. The operative
wound was closed.
A myocardial injury was induced in groups 1, 3, and 4. The
heart was exposed through a left thoracotomy in the fifth
intercostal space. Next, 3 mg of snake toxin from Naja
mossambica mossambica (Sigma Chemical Co, St Louis,
Mo) was dissolved in 1.5 mL sodium chloride (0.9%) and
injected with a disposable syringe connected to a Huber
curved needle (LPI, SA, Bornel, France) into the left ventric-
ular myocardium to induce myocardial injury. The site of the
injury was marked with 3-0 Tevdek suture (Genzyme
Surgical Products, Tucker, Ga) secured with metal ligating
clips (Peters Medico-Surgical Materials, Bobigny, France).
Each sheep was monitored by electrocardiography and the
arterial systemic pressure was measured during the car-
diotoxin injection. Thereafter, a drain was placed in the pleur-
al cavity, and the pericardium, the thorax, the muscles, and
the skin were closed. The drain was removed as soon as the
sheep started spontaneous respiration.
The severity of the myocardial injury was expressed in car-
diac troponin I levels16,17 and was measured 2 hours preoper-
atively and up to 6 days after myocardial injury in groups 1
and 2. The quantitative determination of cardiac troponin I
levels in sheep serum was assessed with a cardiac troponin I
fluorometric enzyme immunoassay (Stratus; Dade Behring,
Inc, Deerfield, Ill). The detection limit was 0.3 ng/mL.
Satellite cell isolation and culture. The explanted skeletal
muscle fragments were washed in phosphate-buffered saline
solution (PBS; Gibco). Adipose tissue and fascia were
removed and the muscle was minced with scissors. The mus-
cle fragments were washed in PBS until the supernatant
remained clear. Centrifugation (Sigma 3K10, Bioblock) was
carried out at 300g for 5 minutes. The PBS was replaced with
20 mL of 0.25% trypsin–ethylenediaminetetraacetic acid
(EDTA) (Gibco) and placed in a 37°C shaking water bath.
After 40 minutes the fragments were forced through a 10-mL
disposable pipette. Once aspiration occurred easily, cells
were filtered through a 40-µm nylon cell strainer (Polylabo
SA, Geneva, Switzerland). Remaining muscle fragments on
the filter were again subjected to enzymatic and mechanical
digestion.
Fetal calf serum (1 mL) (FCS; Gibco) was added to the fil-
trate and the solution was centrifuged at 300g for 20 minutes.
The resulting cell pellets were pooled in 10 mL fresh com-
plete culture medium: 79% Ham-F12 medium, 20% FCS,
and 1% penicillin/streptomycin (Gibco), and plated in a 100-
mm Petri dish. Cell cultures were incubated at 37°C in a
humidified atmosphere containing 5% carbon dioxide.
Passaging of the cultures (1:5 split) was carried out at sub-
confluency to avoid the occurrence of myogenic differentia-
tion at higher densities. During the first passage, pre-plating
was applied, which is based on the quicker attachment of
fibroblasts compared with satellite cells. The satellite cells
were implanted on the third passage.
The number of satellite cells in the primary culture was
determined by immunofluorescence with a desmin primary
antibody (1:20, Sigma) followed by FluoroLink Cy3 (1:200,
Amersham Pharmacia Biotech, Piscataway, NJ) as a second
antibody.
Satellite cell preparation and implantation. Before cell
implantation, the growth medium of each sheep satellite cell
culture was tested aerobically and anaerobically in broth for
its sterility. The Petri dishes (100 mm) containing about 1 ×
106 cells each were washed with PBS. On detachment of the
cells using 2 mL trypsin-EDTA, 2 mL of complete culture
medium was added to each cell suspension. The contents of
the 25 culture dishes were pooled and spun at 300g for 15
minutes. The supernatant was removed and replaced with 20
mL of PBS. The cell concentration and viability were deter-
mined with Trypan blue (Gibco) using a Neubauer hemacy-
tometer (Polylabo). The calculated volume of cell suspension
containing 2 × 107 cells was transferred to a 50-mL tube and
centrifuged at 300g for 5 minutes. The final cell pellet was
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resuspended in 0.5 µL of 0.5% bovine serum albumin (BSA;
Sigma) diluted in Ham-F12 culture medium. 
Three weeks after myocardial injury, satellite cells (group
3) or cell culture media containing 0.5% BSA (group 4) were
injected into the left ventricular lesion. The heart was
exposed by sternotomy. The injured site was identified by a
suture and metal ligating clips (Peters), which were placed at
the time of the injury. Satellite cells or control media were
then injected with a 1-mL syringe guided by echocardiogra-
phy with color kinesis to assure intramyocardial spreading of
the solution. Thereafter, 2 thoracic drains were placed in the
pleural cavity and the thorax was closed with metal wires
(Peters). The wound was further closed in layers. The drains
were removed at the time of extubation.
Echocardiography with color kinesis. Echocardiography
with color kinesis (Sonos 5500; Hewlett-Packard Company,
Palo Alto, Calif) is a new technique based on acoustic quan-
tification, which allows the precise measurement of the
regional wall motion. Color kinesis analyzes regional
backscatter in each acoustic frame in real time and classifies
each pixel as either blood or myocardial tissue. Pixel transi-
tions from blood to tissue during systole are detected and
color-encoded. Color overlays are updated on a frame-by-
frame basis by adding one color at a time (30 frames per sec-
ond). Thus, a single end-systolic frame provides an integrat-
ed display of the timing and magnitude of endocardial wall
motion.20
Regional wall motion measurements were carried out
before cell implantation (group 3) or control medium injec-
tion (group 4) at 3 weeks, as well as 11 weeks after myocar-
dial injury, with the aid of a 7-MHz transducer in the epicar-
dial position. End-systolic frames were used for analysis to
obtain quantitative information because they contain the
entire spatial and temporal histories of the systolic endocar-
dial excursion. Color-encoded images obtained from the
short-axis and apical 4-chamber views were automatically
divided into wedge-shaped segments with the custom-
designed software. These segmentation schemes were used to
minimize the variability caused by individual differences in
left ventricular orientation at end-systole and therefore facil-
itate intersubject comparisons. Regional wall motion was
then assessed by computing the pixel counts in each left ven-
tricular segment. The segments were normalized by the cor-
responding regional end-systolic area to take into account
intersegmental geometric differences and to quantify the
regional fractional area change for each consecutive frame.
In comparison with the regional wall motion, the global car-
diac function was measured at the same time points in the 2-
dimensional mode. The global parameters included the left ven-
tricular end-diastolic and end-systolic diameters, the shortening
fraction, the end-diastolic and end-systolic volumes, and the
ejection fraction. The ejection fraction and shortening fraction
were calculated by the Teicholz method and based on the left
ventricular end-systolic and end-diastolic diameters. All values
were expressed as the mean ± standard deviation and statistical
Student t tests were applied to the results.
Histology. All sheep were euthanized 11 weeks after
myocardial injury. The heart was exposed through a sternoto-
my. Heparin (10,000 IU) and 2 mL of 4% papaverine were
injected intravenously. Thereafter, 20 mL of 10% potassium
chloride was injected intravenously and the beating heart was
excised. The site of the myocardial injury was identified and
dissected. All heart biopsy specimens were frozen in liquid
nitrogen–cooled isopentane (Rectapur; Prolabo). Frozen
biopsy tissue was stored at –80° C until processed on a cryo-
stat (AM 500; Microm, Francheville, France). The tissue was
cut into 10 µm sections. Every 10th and 11th section was col-
ored with hematein-eosin and Masson’s trichrome stains,
respectively. If cells were observed in the myocardial lesion
of these sections, serial sections were tested with a fast
myosin heavy chain (MHC) antibody (MY-32; Sigma), which
is specific for the skeletal isoform of adult fast MHC.
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Fig 1. Cardiac troponin I levels measured in sheep serum 2 hours preoperatively until 6 days after a left ventricu-
lar cardiotoxin injection or sodium chloride as a control.
The sections treated with MHC antibody were first fixed in
ethanol for 15 minutes. Unspecific sites were blocked with
10% FCS in PBS for 30 minutes. The sections were then
incubated with the primary antibody (1:400) in 0.1% FCS for
1 hour, followed by incubation with the secondary antibody,
FluoroLink Cy3–labeled goat anti-mouse immunoglobulin G
(H+L) (1:200, Amersham Pharmacia Biotech) in 0.1% FCS
for 30 minutes. Fluorescence was revealed with an inverted
fluorescent microscope (Nikon Eclipse TE300; Nikon Inc,
Melville, NY) using a rhodamine filter.
Results
Cell culture. Before satellite cell implantation into
the myocardium, cell culture conditions were evaluat-
ed. The primary skeletal muscle cell cultures contained
about 50% myoblasts as determined with desmin
immunofluorescence. All cultures showed 99% viabili-
ty before implantation by means of the trypan blue
exclusion assay. In addition, all cell culture media taken
from the cultures before implantation tested negative
for aerobic and nonaerobic bacterial contaminations.
Myocardial injury. The sheep of groups 1, 3, and 4
underwent myocardial injury by a left ventricular injec-
tion of the snake cardiotoxin Naja mossambica
mossambica with 100% survival. No significant
changes were detected during hemodynamic or pres-
sure measurements at the time of injection. 
Cardiac troponin I was chosen as an indicator of
myocardial infarction. Cardiac troponin I values were
expressed as the mean ± standard deviation in Fig 1.
Blood samples were taken from groups 1 and 2, 2 hours
preoperatively and up to 6 days after cardiotoxin injec-
tion. The cardiotoxin induced a maximum troponin
response in group 1 of 99.5 ng/mL 24 hours after
intramyocardial injection and returned to baseline lev-
els after 4 days. The control group (group 2) reached a
maximum cardiac troponin I concentration of 4.2
ng/mL 3 hours after injection and returned to baseline
values after 2 days.
Macroscopically, a local area of necrosis was consis-
tently observed in the myocardium at the site of car-
diotoxin injection in groups 3 and 4 before cell implan-
tation or control medium injection, respectively, after 3
weeks. Eleven weeks after cardiotoxin injection, the area
of necrosis had developed into an approximately 2-cm3
transmural scar (Fig 2, A). Light microscopic observa-
tions showed a replacement of healthy myocardium with
adipose fibrous tissue in the lesion (Fig 2, B) and the
inflammatory response was extremely low. In addition, a
distinct boundary was noted between healthy and injured
tissue. In the periphery of the lesion, the cardiomyocytes
were often hypertrophic.
Echocardiography with color kinesis. The percent-
age of end-systolic area of the regional left ventricular
wall motion, expressed as regional fractional area
change, showed a significant increase in regional func-
tion from 24% ± 2.8% to 48% ± 9.3% (P < .05) in the
cell-treated group, compared with a nonsignificant
increase from 23.3% ± 5.5% to 30% ± 4.0% in the con-
trol group 11 weeks after myocardial injury. The color-
encoded images, using backscatter, identified the pixel
transition from tissue to blood, which were updated on
a frame-by-frame basis resulting in color overlays. An
example is given in Fig 2, C and D. This figure repre-
sents the regional wall motion of 1 sheep from group 3
observed 3 weeks after myocardial injury (Fig 2, C)
and 2 months after cell implantation (Fig 2, D). A visu-
al comparison in segmental contraction can be made
due to the color overlays. After cell implantation, a
recovery in regional contraction is noted (Fig 2, D)
compared with the limited contraction before cell
implantation (Fig 2, C).
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Table I. Two-dimensional echocardiographic analysis showing global functional results (mean ± SD) for 
cell-treated sheep
Cell-treated group 3
Preimplantation Postimplantation P value: Pre vs post
LVEDD (mm) 41.17 ± 3 37.50 ± 3 .001*
LVESD (mm) 31.50 ± 3 24.50 ± 4 .001*
SF (%) 23.50 ± 5 35.33 ± 6 .007*
EDV (mL) 77.00 ± 10 61.50 ± 10 .0003*
ESV (mL) 39.83 ± 10 22.00 ± 8 .002*
EF (%) 47.17 ± 8 65.00 ± 8 .005*
Measurements were taken 3 and 11 weeks after myocardial injury. LVEDD, Left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension;
SF, shortening fraction; EDV, end-diastolic volume; ESV, end-systolic volume; EF, ejection fraction.
*All parameters were statistically significant.
The results of the 2-dimensional echocardiographic
assessment for global cardiac function are summarized
in Table I. The measurements were carried out 3 and 11
weeks after myocardial injury in group 3. With a paired
Student t test, the 2 time points were compared within
the cell-treated group. A statistical difference was
found for all parameters. 
Histology. Satellite cells were detected in 3 of 6
sheep 8 weeks after cell implantation by means of the
skeletal isoform of adult fast MHC. This antibody did
not react with healthy or cardiotoxin-injured cardiac
sections, nor did it stain the type 1 fibers (slow twitch)
of the skeletal muscle sections. However, the type 2
fibers (fast twitch) also present in the skeletal muscle
sections stained brightly with the fast MHC antibody.
Consequently, the sheep femoral biceps from which the
satellite cells were cultured expressed fast and slow
myosin. Although the satellite cells were injected into
the middle of the lesion with the aid of echocardiogra-
phy with color kinesis, they were identified in the
fibrous tissue on the periphery of the scar close to
healthy cardiac tissue (Fig 3, A, B, and C). No skeletal
muscle cells were observed in healthy myocardium. 
To rule out the possibility that the detected cells with
MHC could be macrophages, we tested an intercellular
adhesion molecule-1 antibody on a serial slide. An anti-
body nonspecific to skeletal muscle was chosen
because macrophages are known to take up any type of
antibody. No fluorescence was observed with the use of
the intercellular adhesion molecule-1 antibody.
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Fig 2. A, Well-defined transmural lesion produced by a cardiotoxin injection into the myocardium of a sheep. B,
Microscopic section of the myocardial lesion stained with Masson trichrome showing cardiomyocytes (c) on the
periphery and fibrous tissue (green) and adipocytes (a) in the lesion (magnification × 10). C, Echocardiography
with color kinesis showing few color overlays in the akinetic region (arrow) of the left ventricular anterior wall in
a 3-week-old myocardial lesion. D, Increase in color overlays representing an improved segmental contraction
(arrow) in the same sheep 2 months after cell implantation.
Consequently, the cells detected with the adult fast
MHC are of skeletal muscle origin with a mature phe-
notype.
Furthermore, elongated skeletal muscle cell struc-
tures (Fig 3, D) were observed resembling myotubes.
However, the possibility that these structures were
closely apposed mononucleated cells could not be ruled
out by light or fluorescence microscopy.
Discussion
Myocardial injury was produced by injecting a car-
diotoxin into the sheep heart muscle. The cobra toxin
from Naja mossambica mossambica is known to cause
muscle necrosis.18 Histologic studies showed that in the
lesion, cardiomyocytes were replaced by fibroblasts
and adipocytes that closely resembled dysplasia.19
Furthermore, myocardial infarction models in sheep
also show a predominant fat tissue infiltration.
The cardiotoxin model was chosen over other models
of myocardial lesion because it requires one single injec-
tion, produces a well-delineated transmural lesion, and
reduces the risk of ventricular fibrillation. Due to the
small lesion, it was possible to implant the cells through-
out the whole lesion. Cryoinjury requires a freezing and
a thawing time of one or more cycles and has an
increased risk of ventricular fibrillation. Moreover, con-
troversial results have been obtained with cryoinjury as
to whether it creates a transmural lesion. Some investi-
gators found that the scar was “quasi-transmural”4 and
that freeze-thaw lesions consist of confluent necrosis in
the subepicardium with viable myocardium in the
subendocardium and are therefore not transmural6; other
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Fig 3. Serial sections of injured sheep myocardium showing implanted skeletal muscle cells (red) stained with (A)
skeletal fast MHC antibodies, (B) hematein and eosin staining, and (C) Masson trichrome staining indicating cell
survival in fibrous tissue (green). Adipocytes (A) were present inside the lesion and cardiomyocytes (C) were noted
on the periphery of the lesion. D, The implanted satellite cells were also found as elongated structures resembling
myotubes (magnifications × 10).
investigators reported that they had obtained a transmur-
al scar.9,11,13 The model of coronary artery ligation is
complicated because of the collateral blood vessels in
the sheep ventricle. Hence, the infarction has to be rela-
tively large so that the collateral blood flow does not heal
the infarcted area. 
Three and 11 weeks after myocardial injury, global
and regional left ventricular function were assessed.
Two-dimensional echocardiography was used to define
the global parameters. This method has been previously
used to study the influence of neonatal muscle cells
transplanted in a coronary artery ligation model in rats.8
Echocardiography with color kinesis was used for
regional measurements of contraction because of the
shortcomings of other methods currently used to assess
the extent and severity of regional wall motion abnor-
malities. These methods imply a manual off-line frame-
by-frame tracing of the myocardial border to evaluate
wall motion. Because it is often difficult to precisely
define the endocardial and epicardial boundaries, these
methods remain subjective. Computerized methods of
edge detection are automated to a great extent. However,
these methods also require off-line processing and have
been successful primarily in the short-axis view. Color
kinesis has been developed to facilitate the evaluation of
regional wall motion. This technique tracks the motion of
the endocardium in real time throughout systole and
results in color-encoded images reflecting the magnitude
and timing of endocardial motion.20
The regional segmental analysis of the injured
myocardium revealed a significant increase in regional
fractional area change from 24% to 48% (P < .05) in
group 3 after cell therapy. In concordance with this
result, the global functional assessment showed a sta-
tistically significant decrease in left ventricular end-
diastolic and end-systolic diameters, together with a
significant increase in shortening fraction and ejection
fraction, which confirmed an amelioration of the left
ventricular function. Therefore, a regional and global
functional improvement was observed in the cell-treat-
ed group when the sheep were used as their own con-
trols. Although the global functional improvement
could be due to the cell implantation, it could also be
caused by compensatory phenomena that act on the
adjacent left ventricular wall close to the myocardial
lesion (left ventricular remodeling process). However,
the regional functional enhancement could only be
brought about by the cell treatment.
In addition to the functional measurements, echocar-
diography with color kinesis proved to be useful to
guide the syringe containing either cells or the culture
media into the myocardium of a beating heart. This
guiding technique led to an optimal delivery of the
solutions because the needle was clearly visible on the
screen, and the dispersion of the cells into the heart tis-
sue was visualized, probably due to a contrast effect
produced by the cells since the culture media only was
not visible.
In 3 of the 6 sheep, cells of skeletal muscle origin
could be identified by means of the skeletal isoform of
an adult fast MHC antibody. In the 3 other sheep, the
implanted cells could not be found. The lack of cells
raises several hypotheses. First, the implanted satellite
cells could have changed from a fast type to a slow type
and since the antibody used to identify the cells was
specific for fast type MHC, cells producing slow type
MHC could not be detected. Beside the fast MHC anti-
body, the cardiac sections containing implanted cells
were tested with a β MHC hybridoma (supernatant
A4.951, Developmental Studies Hybridoma Bank),
which is a major contractile protein in slow fibers.
However, the supernatant was found not to have any
cross-reactivity with sheep. Second, because primary
skeletal muscle cell cultures always contain fibroblasts
that tend to grow faster than satellite cells, it is possible
that, of the implanted cells, the only fibroblasts that had
survived were those that have been shown to improve
ventricular contraction.21 Third, the occurrence of adi-
pose tissue in the myocardial biopsy tissue made it
extremely difficult to slice the mixture of tissues on a
cryostat. These technical difficulties could have pre-
vented the detection of satellite cells in all sheep. 
Immunohistochemical results showed that the
implanted satellite cells were not detected in the center
of the scar. Persistence of the toxin in the center of the
lesion has, therefore, not been excluded. Furthermore,
the implanted cells did not occur in healthy myocardi-
um. Inasmuch as satellite cells can proliferate and even
migrate in response to an injury, Schultz22 and
Bischoff23 speculated that several effector molecules
were released at the site of the skeletal muscle injury,
which induced proliferation and migration of satellite
cells during regeneration. We expected a similar cell
response on injury of the myocardium. Consequently,
the localization of the satellite cells, which were iden-
tified in the fibrous tissue at the periphery of the scar
close to healthy cardiac tissue, suggests that the
implanted cells probably have to be in the proximity of
tissues that have a good blood perfusion. 
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Discussion
Dr G. Hossein Almassi (Milwaukee, Wis). Dr Chachques,
you alluded to the fact that these cells are basically on the
periphery of the scar and dependent on the intact myocardi-
um for survival. Do you see a role for sequential injection of
these cells, as your initial implants take? Could you then pro-
ceed to the second and third injection of a very large scar,
such as can happen in a large myocardial infarction? 
Dr Chachques. We injected the cells in the center of the
scar, and we found only cells surviving in the intermediate
area. In the future, it might be interesting to inject the cells
with angiogenic growth factors to improve the quality of the
tissue for implantation. At this moment we are working with
an endoventricular catheter to implant cells into the ventricu-
lar wall. If one injection is not enough, we can repeat this
kind of therapy several times in the same patient.
Dr Carpentier. It would probably be interesting to com-
bine these multiple injections with laser perforation from the
ventricle so as to provide enough blood supply for the center.
However, up to now we have not been able to see cells in the
center of the necrotic area. 
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